GlassScriptPhysician profile
Andrew M Freeman
NPI 1770748782
$454,382.53
in general payments reported to CMS, 2019-2025
21 companies · $61K in 2025
The $61K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69K · 2020: $61K · 2021: $80K · 2022: $66K · 2023: $62K · 2024: $55K · 2025: $61K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $111K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $53K · Travel and Lodging: $11K · Food and Beverage: $2,803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $111,231.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $52,902.50 |
| Travel and Lodging | $11,340.08 |
| Food and Beverage | $2,802.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $320,519.91 | 2019-2025 | Jardiance |
| Medtronic, INC. | $45,162.73 | 2021-2025 | In.Pact Admiral |
| Ionis Pharmaceuticals, INC. | $14,351.15 | 2025 | Olezarsen |
| Agepha Pharma Fz LLC | $14,238.63 | 2024-2025 | Lodoco |
| Actelion Pharmaceuticals US, INC. | $12,818.24 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| United Therapeutics Corporation | $10,586.34 | 2019-2024 | |
| Pfizer INC. | $10,500.00 | 2023-2024 | |
| Regeneron Pharmaceuticals, INC. | $9,569.03 | 2019 | |
| Novartis Pharmaceuticals Corporation | $5,508.62 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $3,832.00 | 2023-2024 | |
| Cleerly, INC. | $3,200.00 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $2,719.63 | 2022 | |
| Vifor (International) LTD. | $500.00 | 2020 | |
| Medtronic Vascular, INC. | $333.00 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $121.78 | 2025 | Lifevest |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $120.89 | 2025 | |
| Sanofi-Aventis U.S. LLC | $100.00 | 2019 | |
| Merck Sharp & Dohme LLC | $79.23 | 2023 | |
| Amarin Pharma, INC. | $68.52 | 2019 | |
| Philips North America LLC | $27.56 | 2024 | (Ck4) Mcot |
| Heartflow, INC. | $25.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.